Trial reportJournal of lipid research2010
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.
Trial report in Journal of lipid research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.Human molecular genetics · 2022Pooled it
- Meta-analysis for Discovering Rare-Variant Associations: Statistical Methods and Software Programs.American journal of human genetics · 2015Pooled it
- Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Atherosclerosis · 2011Trial
- Epigenetic mediators of diet and lifestyle and insulin resistance.Genes & nutrition · 2026Article
- Article
- Whole Genome Linkage and Association Analyses Identify DLG Associated Protein-1 as a Novel Positional and Biological Candidate Gene for Muscle Strength: The Long Life Family Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Identification of a Novel Locus for Gait Speed Decline With Aging: The Long Life Family Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- ApoB gene polymorphism (rs676210) and its pharmacogenetics impact on atorvastatin response among Iraqi population with coronary artery disease.Journal, genetic engineering & biotechnology · 2021Article
- Polymorphisms in Genes of Lipid Metabolism Are Associated with Type 2 Diabetes Mellitus and Periodontitis, as Comorbidities, and with the Subjects' Periodontal, Glycemic, and Lipid Profiles.Journal of diabetes research · 2021Article
- Gene-environment interactions due to quantile-specific heritability of triglyceride and VLDL concentrations.Scientific reports · 2020Article
- Fibrate pharmacogenomics: expanding past the genome.Pharmacogenomics · 2020Article
- Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.Journal of lipid research · 2018Article
- Integrative methylation score to identify epigenetic modifications associated with lipid changes resulting from fenofibrate treatment in families.BMC proceedings · 2018Article
- An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network.Pharmacogenomics · 2017Article
- DNA methylation as a marker of response in rheumatoid arthritis.Pharmacogenomics · 2017Review
- Higher chylomicron remnants and LDL particle numbers associate with CD36 SNPs and DNA methylation sites that reduce CD36.Journal of lipid research · 2016Article
- A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Pharmacogenetics and genomics · 2016Article
- Sequence and analysis of a whole genome from Kuwaiti population subgroup of Persian ancestry.BMC genomics · 2015Article
- Polymorphisms in ApoB gene are associated with risk of myocardial infarction and serum ApoB levels in a Chinese population.International journal of clinical and experimental medicine · 2015Article
- Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study.Frontiers in genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals. We sought to determine if genetic variation in apolipoprotein B (APOB), an essential core of triglyceride-rich lipoprotein formation, may account for some of the inter-individual differences observed in triglyceride (TG) response to fenofibrate treatment. Participants (N = 958) from the Genetics of Lipid Lowering Drugs and Diet Network study completed a three-week intervention with fenofibrate 160 mg/day. Associations of four APOB gene single nucleotide polymorphisms (SNP) (rs934197, rs693, rs676210, and rs1042031) were tested for association with the TG response to fenofibrate using a mixed growth curve model where the familial structure was modeled as a random effect and cardiovascular risk factors were included as covariates. Three of these four SNPs changed the amino acid sequence of APOB, and the fourth was in the promoter region. TG response to fenofibrate treatment was associated with one APOB SNP, rs676210 (Pro2739Leu), such that participants with the TT genotype of rs676210 had greater TG lowering than those with the CC genotype (additive model, P = 0.0017). We conclude the rs676210 variant may identify individuals who respond best to fenofibrate for TG reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.